-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
High-grade serous carcinoma is one of the most aggressive types of ovarian cancer, and conventional treatments are still very limited
Tumor cells are sometimes so cunning that you may not have imagined how they have so many ways to evade the immune system
Among them, indoleamine 2,3-dioxygenase 1 (IDO1) is a common method used by cancer cells.
In theory, as long as the function of the IDO1 enzyme can be inhibited, the immune system function suppressed by the tumor can be restored
But strangely, some clinical trials have shown that the combination of EPA and immunotherapy is not as effective as scientists thought.
They speculated that when IDO1 was blocked, something unknown was happening in the tumor microenvironment
According to sample analysis, EPA is indeed able to block IDO1-mediated degradation of tryptophan
The increase in the level of NAD+ can also affect the anti-tumor ability of T cells.
▲After the emergence of EPA, the signal pathway of tryptophan degradation was blocked, but other metabolic pathways were activated (Image source: Reference [2])
To this end, Dr.
In a mouse model of ovarian cancer, the researchers used both EPA and purinoceptor antagonists, and the results greatly increased the proliferation of T cells, restoring their ability to kill tumors
Note: The original text has been deleted
References:
[1] New insights into how tumors metabolically adapt to their environment may lead to better cancer therapies.
